Renal Protection for Coronary Angiography in Advanced Renal Failure Patients by Prophylactic HemodialysisA Randomized Controlled Trial
Po-Tsang Lee, MD*, , ,
Kang-Ju Chou, MD*,,
Chun-Peng Liu, MD ,
Guang-Yuan Mar, MD,
Chien-Liang Chen, MD*,,
Chih-Yang Hsu, MD*,
Hua-Chang Fang, MD*,,* and
Hsiao-Min Chung, MD*
* Nephrology
Cardiology, Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan
National Yang-Ming University, School of Medicine, Taipei, Taiwan
Institute of Clinical Medicine, National Cheng Kung University Medical College, Tainan, Taiwan
View larger version (10K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Cr Levels Before Coronary Angiography, on Day 4, at Peak Value, and at Hospital Discharge
Changes in serum creatinine (Cr) values in the dialysis and control groups were assessed using repeated-measures analysis of covariance. Multiple comparisons with the Bonferroni t test were used for the comparisons between and within groups. For the interaction between time and treatment in terms of the Cr level, F statistic = 22.9 (p < 0.001). Changes from baseline in the Cr level were significant at the peak value in the dialysis group (***p = 0.008) and on day 4, at the peak value, and at discharge in the control group (*p < 0.001); the difference between the 2 groups was significant on day 4 and at peak value (**p = 0.010 on day 4; p = 0.005 at peak value).
|
|
View larger version (8K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Renal Outcomes of Dialysis and Control Groups
The bars show significantly different percentages of dialysis and control patients who needed subsequent dialysis (2% vs. 35%; p < 0.001), patients who needed permanent dialysis (0 vs. 13%; p = 0.018), and those with an increase in serum creatinine level between baseline and discharge of at least 1.0 mg/dl (5% vs. 37%; p < 0.001). Fisher exact test was used for the comparison between the groups.
|
|
|
